Why compare them?
These records are compared to clarify how their mechanisms, research areas, and evidence maturity differ.
Simple first. Deeper when you want it.
Understand the differences that matter.
See the biggest similarities, differences, strengths, limitations, and unanswered questions first—then open the evidence behind them.
Compound comparison
SS-31 vs. Cagrilintide
Understand the meaningful overlap, differences, evidence, and unknowns—then go deeper only when you want to.
60-Second Summary
The answer first
Current evidenceComparable evidence base
No direct head-to-head study is represented. This comparison uses separate evidence records that may differ in population, duration, route, dose, and endpoint.
✓ Shared
Shared Similarities
- Both have controlled human research, although the questions and designs may differ.
⇄ Different
Biggest Difference
SS-31 is distinguished by a mitochondrial cardiolipin-binding tetrapeptide with a narrow accelerated approval—not a receptor agonist or a general-purpose energy peptide; Cagrilintide is distinguished by long-acting amylin analogue with amylin- and calcitonin-receptor activity; it is not a GLP-1 receptor agonist and is not the same evidence record as CagriSema.
? Unknown
Biggest Unknown
No direct head-to-head study establishes how these compounds compare under the same population, dose, duration, and endpoints.
Key Takeaways
SS-31 is distinguished in the current record by a mitochondrial cardiolipin-binding tetrapeptide with a narrow accelerated approval—not a receptor agonist or a general-purpose energy peptide. Cagrilintide is distinguished by long-acting amylin analogue with amylin- and calcitonin-receptor activity; it is not a GLP-1 receptor agonist and is not the same evidence record as CagriSema. Neither is objectively “better”; the useful question is which evidence record addresses the research question being asked.
Research matrix
Which question has stronger current support?
Research questionStronger current supportExplanation
Human evidenceSS-31
SS-31: Mixed human evidence. Cagrilintide: Developing human evidence.
Regulatory historySS-31
SS-31: Narrow FDA accelerated approval. Cagrilintide: Investigational — Phase 3.
Mechanistic breadthCagrilintide
More named targets describes mechanistic breadth; it does not establish greater effectiveness.
Direct comparisonUnknown
Separate studies cannot establish comparative superiority.
Deeper when you want it
Explore the evidence and nuance
Best-studied areas and pathway mapSee shared targets, unique pathways, and the research questions attached to each record.
SS-31
- Barth syndrome
- Primary mitochondrial myopathy
- Dry age-related macular degeneration
- Heart failure
Cagrilintide
- Weight management
- Appetite and energy intake
- Obesity with type 2 diabetes
- Visceral and ectopic fat
Pathway and research map
Shared foundation and unique questions
Research confidence by questionCompare regulatory, human-evidence, outcome, and administration records side by side.
Question by question
What each evidence base can actually answer
Regulatory statusEvidence, not a winner
SS-31Narrow accelerated approval
FDA accelerated approval as FORZINITY to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg. Other uses remain unapproved.
CagrilintideInvestigational
Investigational. No FDA-approved standalone cagrilintide product, consumer dose, reconstitution method, or official storage procedure.
Evidence depthEvidence, not a winner
SS-31Mixed controlled trials
A very small Barth program, a negative 218-participant Phase 3 primary-mitochondrial-myopathy trial, negative primary outcomes in Phase 2 heart-failure and dry-AMD trials, and recruiting confirmatory programs.
CagrilintidePhase 2 + Phase 3 pending
One published 706-participant Phase 2 monotherapy trial, a 105-participant thorough-QT study, sponsor-reported Phase 3 component-arm data, and two active dedicated Phase 3 RENEW trials without posted results.
Weight outcomesEvidence, not a winner
SS-31No dedicated benefit
No controlled human weight-management or body-composition benefit has been established.
CagrilintidePeer-reviewed Phase 2
Phase 2 reported mean reductions of 6.0% to 10.8% across studied cagrilintide arms versus 3.0% placebo at 26 weeks. A sponsor-reported Phase 3 component arm later reported 11.8% versus 2.3% at 68 weeks under an efficacy estimand.
Type 2 diabetesEvidence, not a winner
SS-31No approved indication
No FDA-approved diabetes indication or completed controlled diabetes-outcome program was located.
CagrilintidePhase 3 registered
RENEW 2 is studying standalone cagrilintide in adults with overweight or obesity and type 2 diabetes; no results were posted by the cutoff.
Obstructive sleep apnoeaEvidence, not a winner
SS-31No dedicated evidence
No dedicated controlled human obstructive-sleep-apnoea outcome study was located.
CagrilintideNo dedicated evidence
No dedicated completed controlled human obstructive-sleep-apnoea outcome study was located.
Cardiovascular outcomesEvidence, not a winner
SS-31Negative Phase 2 primary outcome
The 71-participant PROGRESS-HF trial did not improve left-ventricular end-systolic volume or ejection fraction over four weeks. Barth cardiac observations come from a tiny uncontrolled extension.
CagrilintideQT study only
A 105-participant thorough-QT study found no clinically relevant QTc prolongation at the tested exposure. That narrow result is not a cardiovascular outcomes trial.
Administration and handlingEvidence, not a winner
SS-31FORZINITY label only
FORZINITY has product-specific FDA labeling as a ready-to-use once-daily subcutaneous solution. That label does not establish dosing, reconstitution, compatibility, or storage for powdered or unverified SS-31 materials.
CagrilintideTrial descriptions only
Published and registered studies describe once-weekly subcutaneous administration under protocol-specific escalation. These are trial descriptions, not approved dosing instructions.
Comparison limitationsUnderstand what this comparison cannot establish before interpreting separate studies.
Comparable evidence base
- No direct head-to-head trial is represented for this pair.
- Separate studies may use different populations, endpoints, durations, doses, routes, and estimands.
- Results should not be interpreted as comparative superiority or individual guidance.
Current unknowns
Questions the evidence cannot answer yet
- Whether the intermediate strength endpoint predicts meaningful functional benefit, plus long-term safety and efficacy outside Barth syndrome.
- Whether the dedicated RENEW Phase 3 trials confirm long-term standalone efficacy and safety in people with and without type 2 diabetes.
Community Intelligence
Emerging patterns, clearly separated from evidence
SS-31
No community experiences yetBe the first account holder to contribute.
Cagrilintide
No community experiences yetBe the first account holder to contribute.
Community Intelligence summarizes structured, self-reported experiences. It can reveal patterns and useful research questions, but it cannot prove safety, effectiveness, or cause and effect. Published evidence is always shown separately.